Loading…

Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients

Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patien...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology- oncology and stem cell research 2022, Vol.16 (1), p.9-14
Main Authors: Shaiegan, Mojgan, Moghaddam, Mostafa, Maghsudlu, Mahtab, Azarkeivan, Azita, Zolfaghari, Sima, Pourfatollah, Ali-Akbar, Soleimanzadeh, Peyman, Shahverdi, Ehsan
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 14
container_issue 1
container_start_page 9
container_title International journal of hematology- oncology and stem cell research
container_volume 16
creator Shaiegan, Mojgan
Moghaddam, Mostafa
Maghsudlu, Mahtab
Azarkeivan, Azita
Zolfaghari, Sima
Pourfatollah, Ali-Akbar
Soleimanzadeh, Peyman
Shahverdi, Ehsan
description Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patients with thalassemia referring to the Iranian Blood Transfusion Organization (IBTO) Immunohematology Reference Laboratory (IRL) in Tehran. Materials and Methods: This study first examined the laboratory records of 23,113 patients suffering from different diseases referring to IBTO’s IRL for pretransfusion testing in the 2008-2015 period. ABO and Rh(D) typing and antibody screening tests were performed for all 23,113 patient records and 685 (2.97%) beta-thalassemia patients with positive pre-transfusion test results (antibody screening and/or DAT) were selected for further investigation. Results: The antibody screening test was positive in 640 out of 685 thalassemic patients (93.4%). DAT was performed for 529 patients, 226 (33%) of which showed positive results. Meanwhile, 161 out of 685 beta-thalassemia patients (23.5%) had positive auto control test results, reflecting the possible presence of allo- and/or autoantibodies. The most common antigen-specific alloantibodies were directed against K and E RBC antigens with a frequency of 25% (Anti-K) and 11.91% (Anti-E), respectively. The development of two antibodies (double antibodies) in one patient was observed in 80 individuals (11.46%). Conclusion: Age, gender, history of pregnancy, and splenectomy were not contributing factors to the antibody presence in the patient population under study. Extended red blood cell phenotyping should be considered as an essential procedure for expected multi-transfused thalassemia patients before blood transfusion. Considering the high frequency of anti-K and anti-E observed in this study, it is recommended that thalassemia patients in Iran are tested through phenotyping of RBC units for K and E antigens before transfusion.  
doi_str_mv 10.18502/ijhoscr.v16i1.8435
format article
fullrecord <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3e7a9a02b198429ab63828ad14879120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3e7a9a02b198429ab63828ad14879120</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_9339119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3135-b0872cfc9278fed6aa14f2459a5d272146746fad8c2b28eccf78a6dd6bf4d8973</originalsourceid><addsrcrecordid>eNpVkdtKAzEQhoMoWrRP4E1eoDWH3RxuBC1WCwVF6nWYTbJtyu5Gkm1Bn961FdG5meEf5oPhQ-iakilVJWE3YbuJ2abpnopAp6rg5QkaMULUhDEiT__MF2ic85YMxZUmkp6jC15qWVIqRujl1Tt838To8Mw3DV607a4Ln9CH2GHohjR2fQrVrg_dGs_B9jFlHDosVIlXG2ggZ98GwC_Die_6fIXOamiyH__0S_Q2f1jNnibL58fF7G45sZzyclIRJZmtrWZS1d4JAFrUrCg1lI5JRgshC1GDU5ZVTHlra6lAOCequnBKS36JFkeui7A17ym0kD5MhGAOQUxrA6kPtvGGewkaCKuoVgXTUAmumAJHCyU1ZWRg3R5Z77uq9c4OfyRo_kH_b7qwMeu4N5pzTakeAPwIsCnmnHz9e0uJOfgyP77MwZf59sW_AHWZii0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients</title><source>PubMed Central</source><creator>Shaiegan, Mojgan ; Moghaddam, Mostafa ; Maghsudlu, Mahtab ; Azarkeivan, Azita ; Zolfaghari, Sima ; Pourfatollah, Ali-Akbar ; Soleimanzadeh, Peyman ; Shahverdi, Ehsan</creator><creatorcontrib>Shaiegan, Mojgan ; Moghaddam, Mostafa ; Maghsudlu, Mahtab ; Azarkeivan, Azita ; Zolfaghari, Sima ; Pourfatollah, Ali-Akbar ; Soleimanzadeh, Peyman ; Shahverdi, Ehsan</creatorcontrib><description>Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patients with thalassemia referring to the Iranian Blood Transfusion Organization (IBTO) Immunohematology Reference Laboratory (IRL) in Tehran. Materials and Methods: This study first examined the laboratory records of 23,113 patients suffering from different diseases referring to IBTO’s IRL for pretransfusion testing in the 2008-2015 period. ABO and Rh(D) typing and antibody screening tests were performed for all 23,113 patient records and 685 (2.97%) beta-thalassemia patients with positive pre-transfusion test results (antibody screening and/or DAT) were selected for further investigation. Results: The antibody screening test was positive in 640 out of 685 thalassemic patients (93.4%). DAT was performed for 529 patients, 226 (33%) of which showed positive results. Meanwhile, 161 out of 685 beta-thalassemia patients (23.5%) had positive auto control test results, reflecting the possible presence of allo- and/or autoantibodies. The most common antigen-specific alloantibodies were directed against K and E RBC antigens with a frequency of 25% (Anti-K) and 11.91% (Anti-E), respectively. The development of two antibodies (double antibodies) in one patient was observed in 80 individuals (11.46%). Conclusion: Age, gender, history of pregnancy, and splenectomy were not contributing factors to the antibody presence in the patient population under study. Extended red blood cell phenotyping should be considered as an essential procedure for expected multi-transfused thalassemia patients before blood transfusion. Considering the high frequency of anti-K and anti-E observed in this study, it is recommended that thalassemia patients in Iran are tested through phenotyping of RBC units for K and E antigens before transfusion.  </description><identifier>ISSN: 2008-2207</identifier><identifier>ISSN: 2008-3009</identifier><identifier>EISSN: 2008-2207</identifier><identifier>DOI: 10.18502/ijhoscr.v16i1.8435</identifier><identifier>PMID: 35975116</identifier><language>eng</language><publisher>Tehran, Iran: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center</publisher><subject>Alloimmunization; Thalassemia; Anti-K; Antibody identification (ABID); Direct antiglobulin test (DAT) ; Original</subject><ispartof>International journal of hematology- oncology and stem cell research, 2022, Vol.16 (1), p.9-14</ispartof><rights>Copyright © 2022 Tehran University of Medical Sciences.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339119/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339119/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Shaiegan, Mojgan</creatorcontrib><creatorcontrib>Moghaddam, Mostafa</creatorcontrib><creatorcontrib>Maghsudlu, Mahtab</creatorcontrib><creatorcontrib>Azarkeivan, Azita</creatorcontrib><creatorcontrib>Zolfaghari, Sima</creatorcontrib><creatorcontrib>Pourfatollah, Ali-Akbar</creatorcontrib><creatorcontrib>Soleimanzadeh, Peyman</creatorcontrib><creatorcontrib>Shahverdi, Ehsan</creatorcontrib><title>Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients</title><title>International journal of hematology- oncology and stem cell research</title><description>Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patients with thalassemia referring to the Iranian Blood Transfusion Organization (IBTO) Immunohematology Reference Laboratory (IRL) in Tehran. Materials and Methods: This study first examined the laboratory records of 23,113 patients suffering from different diseases referring to IBTO’s IRL for pretransfusion testing in the 2008-2015 period. ABO and Rh(D) typing and antibody screening tests were performed for all 23,113 patient records and 685 (2.97%) beta-thalassemia patients with positive pre-transfusion test results (antibody screening and/or DAT) were selected for further investigation. Results: The antibody screening test was positive in 640 out of 685 thalassemic patients (93.4%). DAT was performed for 529 patients, 226 (33%) of which showed positive results. Meanwhile, 161 out of 685 beta-thalassemia patients (23.5%) had positive auto control test results, reflecting the possible presence of allo- and/or autoantibodies. The most common antigen-specific alloantibodies were directed against K and E RBC antigens with a frequency of 25% (Anti-K) and 11.91% (Anti-E), respectively. The development of two antibodies (double antibodies) in one patient was observed in 80 individuals (11.46%). Conclusion: Age, gender, history of pregnancy, and splenectomy were not contributing factors to the antibody presence in the patient population under study. Extended red blood cell phenotyping should be considered as an essential procedure for expected multi-transfused thalassemia patients before blood transfusion. Considering the high frequency of anti-K and anti-E observed in this study, it is recommended that thalassemia patients in Iran are tested through phenotyping of RBC units for K and E antigens before transfusion.  </description><subject>Alloimmunization; Thalassemia; Anti-K; Antibody identification (ABID); Direct antiglobulin test (DAT)</subject><subject>Original</subject><issn>2008-2207</issn><issn>2008-3009</issn><issn>2008-2207</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkdtKAzEQhoMoWrRP4E1eoDWH3RxuBC1WCwVF6nWYTbJtyu5Gkm1Bn961FdG5meEf5oPhQ-iakilVJWE3YbuJ2abpnopAp6rg5QkaMULUhDEiT__MF2ic85YMxZUmkp6jC15qWVIqRujl1Tt838To8Mw3DV607a4Ln9CH2GHohjR2fQrVrg_dGs_B9jFlHDosVIlXG2ggZ98GwC_Die_6fIXOamiyH__0S_Q2f1jNnibL58fF7G45sZzyclIRJZmtrWZS1d4JAFrUrCg1lI5JRgshC1GDU5ZVTHlra6lAOCequnBKS36JFkeui7A17ym0kD5MhGAOQUxrA6kPtvGGewkaCKuoVgXTUAmumAJHCyU1ZWRg3R5Z77uq9c4OfyRo_kH_b7qwMeu4N5pzTakeAPwIsCnmnHz9e0uJOfgyP77MwZf59sW_AHWZii0</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Shaiegan, Mojgan</creator><creator>Moghaddam, Mostafa</creator><creator>Maghsudlu, Mahtab</creator><creator>Azarkeivan, Azita</creator><creator>Zolfaghari, Sima</creator><creator>Pourfatollah, Ali-Akbar</creator><creator>Soleimanzadeh, Peyman</creator><creator>Shahverdi, Ehsan</creator><general>Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center</general><general>Tehran University of Medical Sciences</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2022</creationdate><title>Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients</title><author>Shaiegan, Mojgan ; Moghaddam, Mostafa ; Maghsudlu, Mahtab ; Azarkeivan, Azita ; Zolfaghari, Sima ; Pourfatollah, Ali-Akbar ; Soleimanzadeh, Peyman ; Shahverdi, Ehsan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3135-b0872cfc9278fed6aa14f2459a5d272146746fad8c2b28eccf78a6dd6bf4d8973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alloimmunization; Thalassemia; Anti-K; Antibody identification (ABID); Direct antiglobulin test (DAT)</topic><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shaiegan, Mojgan</creatorcontrib><creatorcontrib>Moghaddam, Mostafa</creatorcontrib><creatorcontrib>Maghsudlu, Mahtab</creatorcontrib><creatorcontrib>Azarkeivan, Azita</creatorcontrib><creatorcontrib>Zolfaghari, Sima</creatorcontrib><creatorcontrib>Pourfatollah, Ali-Akbar</creatorcontrib><creatorcontrib>Soleimanzadeh, Peyman</creatorcontrib><creatorcontrib>Shahverdi, Ehsan</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>International journal of hematology- oncology and stem cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shaiegan, Mojgan</au><au>Moghaddam, Mostafa</au><au>Maghsudlu, Mahtab</au><au>Azarkeivan, Azita</au><au>Zolfaghari, Sima</au><au>Pourfatollah, Ali-Akbar</au><au>Soleimanzadeh, Peyman</au><au>Shahverdi, Ehsan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients</atitle><jtitle>International journal of hematology- oncology and stem cell research</jtitle><date>2022</date><risdate>2022</risdate><volume>16</volume><issue>1</issue><spage>9</spage><epage>14</epage><pages>9-14</pages><issn>2008-2207</issn><issn>2008-3009</issn><eissn>2008-2207</eissn><abstract>Background: An analysis of red blood cell alloimmunization in patients with thalassemia can help to devise specific strategies to decrease the alloimmunization rate. This study explored the frequency and specificity of alloantibodies and autoantibodies against red blood cell (RBC) antigens in patients with thalassemia referring to the Iranian Blood Transfusion Organization (IBTO) Immunohematology Reference Laboratory (IRL) in Tehran. Materials and Methods: This study first examined the laboratory records of 23,113 patients suffering from different diseases referring to IBTO’s IRL for pretransfusion testing in the 2008-2015 period. ABO and Rh(D) typing and antibody screening tests were performed for all 23,113 patient records and 685 (2.97%) beta-thalassemia patients with positive pre-transfusion test results (antibody screening and/or DAT) were selected for further investigation. Results: The antibody screening test was positive in 640 out of 685 thalassemic patients (93.4%). DAT was performed for 529 patients, 226 (33%) of which showed positive results. Meanwhile, 161 out of 685 beta-thalassemia patients (23.5%) had positive auto control test results, reflecting the possible presence of allo- and/or autoantibodies. The most common antigen-specific alloantibodies were directed against K and E RBC antigens with a frequency of 25% (Anti-K) and 11.91% (Anti-E), respectively. The development of two antibodies (double antibodies) in one patient was observed in 80 individuals (11.46%). Conclusion: Age, gender, history of pregnancy, and splenectomy were not contributing factors to the antibody presence in the patient population under study. Extended red blood cell phenotyping should be considered as an essential procedure for expected multi-transfused thalassemia patients before blood transfusion. Considering the high frequency of anti-K and anti-E observed in this study, it is recommended that thalassemia patients in Iran are tested through phenotyping of RBC units for K and E antigens before transfusion.  </abstract><cop>Tehran, Iran</cop><pub>Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center</pub><pmid>35975116</pmid><doi>10.18502/ijhoscr.v16i1.8435</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2008-2207
ispartof International journal of hematology- oncology and stem cell research, 2022, Vol.16 (1), p.9-14
issn 2008-2207
2008-3009
2008-2207
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3e7a9a02b198429ab63828ad14879120
source PubMed Central
subjects Alloimmunization
Thalassemia
Anti-K
Antibody identification (ABID)
Direct antiglobulin test (DAT)
Original
title Red Blood Cell Immunization and Contributing Factors in 685 Thalassemia Patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A01%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Red%20Blood%20Cell%20Immunization%20and%20Contributing%20Factors%20in%20685%20Thalassemia%20Patients&rft.jtitle=International%20journal%20of%20hematology-%20oncology%20and%20stem%20cell%20research&rft.au=Shaiegan,%20Mojgan&rft.date=2022&rft.volume=16&rft.issue=1&rft.spage=9&rft.epage=14&rft.pages=9-14&rft.issn=2008-2207&rft.eissn=2008-2207&rft_id=info:doi/10.18502/ijhoscr.v16i1.8435&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_9339119%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3135-b0872cfc9278fed6aa14f2459a5d272146746fad8c2b28eccf78a6dd6bf4d8973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/35975116&rfr_iscdi=true